Joint Position Paper on Pharmaceutical Excipient Testing and Control Strategies - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Joint Position Paper on Pharmaceutical Excipient Testing and Control Strategies
This article presents collaborative positions among excipient manufacturers, drug product manufacturers, and members of the US Pharmacopeia on key issues pertaining to the control of pharmaceutical excipients stemming from a recent Pharmaceutical Quality Research Institute workshop.

Pharmaceutical Technology

Also Section 501(a)(2)(B) of the FD&C Act requires that drugs, including excipients meeting the definition of a drug in Section 201(g) of the Act, be manufactured in conformance with current good manufacturing practice. Hence, according to the Act, all excipients intended for use in the manufacture of a drug product, whether or not the excipient is listed in the official USP–NF, must be manufactured in conformance with current good manufacturing practice. However, FDA has not promulgated CGMP regulations for excipients. CGMP regulations in 21 CFR Parts 210 and 211 apply to the manufacture of finished drug products and not to the manufacturing of APIs or excipients. Therefore, GMP guidance for pharmaceutical excipients has been jointly published by IPEC and PQG (15).

Issue of excipient manufacturers removing USP or NF designation from the label. During the workshop it was noted that some manufacturers of pharmaceutical excipients remove the USP or NF designation from labeling to avoid having to conform to CGMP and official USP–NF standards. FDA noted, however, that removing the USP or NF labeling does not obviate the requirement to meet applicable CGMP and official USP–NF standards.

Workshop participants highlighted several questions and answers. The first question was, What is industry's burden in supplying analytical methods validation data to regulatory agency for excipients no longer labeled USP or NF? This is an important topic, and there was no real answer at the conference. However, a drug-product manufacturer must find out the reason for the excipient manufacturer's removal of the USP or NF designation. Possible reasons include the manufacturer's inability to meet specification or GMP issues. If the reason is specification issues, excipient manufacturers can work with USP. For GMP issues, a drug-product manufacturer must carefully assess the suitability of its supplier's GMPs for the intended use. If the supplier stopped designating the excipient as USP or NF for GMP reasons, then the material from such a supplier should not be used, and a different acceptable supplier for that material should be found.

A second question was, If the drug manufacturer references the excipient manufacturer's DMF, does the drug manufacturer need to supply the analytical methods validation data? The answer was that no additional analytical methods validation data need to be supplied in an abbreviated new drug application (ANDA) or NDA if FDA determines the DMF to be adequate in support of an application.

After the workshop, the PQRI Excipient Working Group discussed the regulatory and implementation recommendations to address these two topics. These recommendations are summarized in the following paragraphs.

Analytical methods validation data for noncompendial analytical procedures used for testing noncompendial designated excipients. When an excipient manufacturer or drug-product manufacturer uses a noncompendial (or other FDA-recognized public standard) analytical procedure for testing a not-novel, noncompendial-designated component for which official USP–NF monograph exists, the analytical methods validation data for such test procedures should be made available for review by the regulatory agency (e.g., FDA) at the site of excipient testing. If the excipient manufacturer were to submit the alternative analytical procedure and its analytical methods validation data in a Type 4 DMF, then the drug product manufacturers can reference it in their drug applications and need not submit the same information again for the agency's review (16, 17).

A not-novel or a new excipient can be a non-GRAS (referenced as substances Generally Recognized As Safe, according to 21 CFR Parts 182, 184, and 186) component used for the first time in a human drug product, or a previously used drug-product component proposed for use in higher quantity per dose or per daily human exposure, or by a new route of administration, or for a longer duration of human use than previously evaluated and allowed by FDA. Additional details on this subject can be found in FDA's Guidance for Industry (18, 19).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here